Navtemadlin

Generic Name: Navtemadlin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₅Cl_₂NO_₅S

CAS Number: 1352066-68-2

Unique Ingredient Identifier: 7R7G6EH5UL

Background: Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Interventions: Drug: Cytarabine
Drug: Idarubicin Hydrochloride
Drug: Navtemadlin

First Posted Date: 2019-12-09

Last Posted Date: 2024-12-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT04190550

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 3 locations

Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

Phase 1

Active, not recruiting

Conditions: Resectable Soft Tissue Sarcoma
Soft Tissue Sarcoma

Interventions: Drug: Navtemadlin
Radiation: Radiation Therapy
Procedure: Surgical Procedure

First Posted Date: 2017-07-14

Last Posted Date: 2024-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT03217266

Locations: 🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 50 locations

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Phase 1

Suspended

Conditions: Recurrent Glioblastoma
Gliosarcoma
MGMT-Unmethylated Glioblastoma
Glioblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Drug: Navtemadlin
Radiation: Radiation Therapy

First Posted Date: 2017-04-11

Last Posted Date: 2024-11-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 86

Registration Number: NCT03107780

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 8 locations

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Phase 1

Suspended

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Decitabine
Drug: Navtemadlin
Drug: Venetoclax

First Posted Date: 2017-02-03

Last Posted Date: 2024-08-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT03041688

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 10 locations

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Plasmacytoma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Dexamethasone Sodium Phosphate
Procedure: Echocardiography
Drug: Lenalidomide
Drug: Navtemadlin

First Posted Date: 2017-01-26

Last Posted Date: 2024-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT03031730

Locations: 🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸
University of Texas at Austin, Austin, Texas, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 4 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy